Novo Nordisk

Novo Nordisk Braces for Defining Week as Medicare Deal and Phase 3 CagriSema Data Converge

Wegovy Pill’s Quick Start Sets Stage for Novo Nordisk’s Next Data Catalyst

Novo Nordisk: A New Indication Beckons Even as Patent Walls Crumble in Emerging Markets

kashif hafeez -

Novo Nordisk’s Pipeline Hope Meets Commercial Reality: India Clearance and CVS Reversal Collide

Catalysts and Clouds Collide for Novo Nordisk: Oral Wegovy Nears EU Launch While Safety Study Spurs Caution

Brett Shapiro -

Novo Nordisk Juggles Pipeline Ambitions and Pill Expansion as Profit Pressure Mounts

angelina -

Novo Nordisk Lifts Guidance on Oral Wegovy Adoption and Compelling Fat-Loss Data

Novo Nordisk Tightens Domestic Operations as Obesity Pipeline Gathers Momentum

kashif hafeez -

At Istanbul Congress, Novo Nordisk Unveils Data Blitz While Oral Wegovy Races Past 2 Million Prescriptions

Novo Nordisk’s Logistics Win Offers a Lift, but the Washington Headache Is Just Beginning

Novo Nordisk’s Twin Clinical Wins Mask a Bruising Year and a Looming Medicare Showdown

angelina -

Novo Nordisk’s US Offensive and Buyback Battle a Steidous Share Price Slide

angelina -

Novo Nordisk Faces Shifting Competitive Landscape in Weight-Loss Drug Market

kashif hafeez -

Novo Nordisk’s Strategic Pivot: A High-Stakes Bet on Liver Disease

Brett Shapiro -

Novo Nordisk Forges Strategic Partnership Following Legal Dispute Resolution

angelina -
12345Page 3 of 5